Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
Identifieur interne : 000652 ( PubMed/Checkpoint ); précédent : 000651; suivant : 000653Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
Auteurs : Michel Panisset [Canada] ; Jack J. Chen ; Sean H. Rhyee ; Jill Conner ; Julie MathenaSource :
- Pharmacotherapy [ 1875-9114 ] ; 2014.
Descripteurs français
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents, Second-Generation (administration & dosage), Antidepressive Agents, Second-Generation (adverse effects), Cohort Studies, Drug Interactions, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Indans (administration & dosage), Indans (adverse effects), Male, Middle Aged, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine Oxidase Inhibitors (adverse effects), Parkinson Disease (drug therapy), Retrospective Studies, Serotonin Uptake Inhibitors (administration & dosage), Serotonin Uptake Inhibitors (adverse effects), United States.
- MESH :
- chemical , administration & dosage : Antidepressive Agents, Second-Generation, Indans, Monoamine Oxidase Inhibitors, Serotonin Uptake Inhibitors.
- chemical , adverse effects : Antidepressive Agents, Second-Generation, Indans, Monoamine Oxidase Inhibitors, Serotonin Uptake Inhibitors.
- geographic : United States.
- drug therapy : Parkinson Disease.
- Aged, Cohort Studies, Drug Interactions, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Middle Aged, Retrospective Studies.
Abstract
The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants.
DOI: 10.1002/phar.1500
PubMed: 25314256
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25314256Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).</title><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Notre-Dame du CHUM, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Hôpital Notre-Dame du CHUM, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Jack J" sort="Chen, Jack J" uniqKey="Chen J" first="Jack J" last="Chen">Jack J. Chen</name></author><author><name sortKey="Rhyee, Sean H" sort="Rhyee, Sean H" uniqKey="Rhyee S" first="Sean H" last="Rhyee">Sean H. Rhyee</name></author><author><name sortKey="Conner, Jill" sort="Conner, Jill" uniqKey="Conner J" first="Jill" last="Conner">Jill Conner</name></author><author><name sortKey="Mathena, Julie" sort="Mathena, Julie" uniqKey="Mathena J" first="Julie" last="Mathena">Julie Mathena</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25314256</idno><idno type="pmid">25314256</idno><idno type="doi">10.1002/phar.1500</idno><idno type="wicri:Area/PubMed/Corpus">000634</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000634</idno><idno type="wicri:Area/PubMed/Curation">000634</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000634</idno><idno type="wicri:Area/PubMed/Checkpoint">000634</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000634</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).</title><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Notre-Dame du CHUM, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Hôpital Notre-Dame du CHUM, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Jack J" sort="Chen, Jack J" uniqKey="Chen J" first="Jack J" last="Chen">Jack J. Chen</name></author><author><name sortKey="Rhyee, Sean H" sort="Rhyee, Sean H" uniqKey="Rhyee S" first="Sean H" last="Rhyee">Sean H. Rhyee</name></author><author><name sortKey="Conner, Jill" sort="Conner, Jill" uniqKey="Conner J" first="Jill" last="Conner">Jill Conner</name></author><author><name sortKey="Mathena, Julie" sort="Mathena, Julie" uniqKey="Mathena J" first="Julie" last="Mathena">Julie Mathena</name></author></analytic><series><title level="j">Pharmacotherapy</title><idno type="eISSN">1875-9114</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antidepressive Agents, Second-Generation (administration & dosage)</term><term>Antidepressive Agents, Second-Generation (adverse effects)</term><term>Cohort Studies</term><term>Drug Interactions</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Female</term><term>Humans</term><term>Indans (administration & dosage)</term><term>Indans (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (administration & dosage)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Retrospective Studies</term><term>Serotonin Uptake Inhibitors (administration & dosage)</term><term>Serotonin Uptake Inhibitors (adverse effects)</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antidepressive Agents, Second-Generation</term><term>Indans</term><term>Monoamine Oxidase Inhibitors</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antidepressive Agents, Second-Generation</term><term>Indans</term><term>Monoamine Oxidase Inhibitors</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cohort Studies</term><term>Drug Interactions</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25314256</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>23</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2014</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9114</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pharmacotherapy</Title><ISOAbbreviation>Pharmacotherapy</ISOAbbreviation></Journal><ArticleTitle>Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).</ArticleTitle><Pagination><MedlinePgn>1250-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.1500</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess systematically the occurrence of STS in patients with Parkinson disease (PD) treated with rasagiline plus antidepressants (R+ATD), rasagiline without antidepressants (R), or antidepressants plus anti-PD dopaminergic medications (ATD) other than either rasagiline or selegiline.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A phase IV multicenter retrospective cohort study was conducted of patients with PD who began receiving R+ATD, R, or ATD between September 1, 2006, and December 31, 2008. Medical records were reviewed for patient demographics, treatment details, and hospitalizations/emergency department (ED) visits. An adjudication committee independently reviewed records to verify case ascertainment and used the Hunter Serotonin Toxicity Criteria for case definition. Outcome variables were analyzed by descriptive statistics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1504 patients with PD (471 with R+ATD; 511 with R; and 525 with ATD) were enrolled from 37 sites. In the R+ATD and ATD groups, selective serotonin reuptake inhibitors (SSRIs) were most frequently used (74.5% and 77%, respectively). In the R+ATD and ATD groups, mean duration of antidepressant use (tricyclic, SSRI, and other) were 50.5-53.5 weeks and 51.7-80.9 weeks, respectively. Overall, 195 patients (13%) from all three groups had one or more hospitalization/ED visits. No cases of STS were identified in any group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large multicenter retrospective cohort study, concurrent administration of R+ATD was not associated with STS. The findings of this phase IV study expand the drug interaction and pharmacovigilance safety awareness for the use of antidepressants in patients with PD.</AbstractText><CopyrightInformation>© 2014 Pharmacotherapy Publications, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panisset</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hôpital Notre-Dame du CHUM, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jack J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Rhyee</LastName><ForeName>Sean H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Conner</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mathena</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><CollectiveName>STACCATO study investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacotherapy</MedlineTA><NlmUniqueID>8111305</NlmUniqueID><ISSNLinking>0277-0008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">antidepressants</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">parkinsonism</Keyword><Keyword MajorTopicYN="N">rasagiline</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Aminoff</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonwetsch</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dalvi</LastName><ForeName>Arif</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edelsohn</LastName><ForeName>Lanny</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elmer</LastName><ForeName>Lawrence W</ForeName><Initials>LW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Factor</LastName><ForeName>Stewart A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farris</LastName><ForeName>Sierra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forchetti</LastName><ForeName>Concetta M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furr-Stimming</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gould</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermanowicz</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hersh</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hogan</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Houser</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchman</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isaacson</LastName><ForeName>Stuart H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreitzman</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kresa-Reahl</LastName><ForeName>Kiren</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lessig</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Grace S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ondo</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perel</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plotkin</LastName><ForeName>George M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preston</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shubin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silver</LastName><ForeName>Dee E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simuni</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Standaert</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struck</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sutton</LastName><ForeName>James P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swope</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varipapa</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Ronald E</ForeName><Initials>RE</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25314256</ArticleId><ArticleId IdType="doi">10.1002/phar.1500</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Chen, Jack J" sort="Chen, Jack J" uniqKey="Chen J" first="Jack J" last="Chen">Jack J. Chen</name><name sortKey="Conner, Jill" sort="Conner, Jill" uniqKey="Conner J" first="Jill" last="Conner">Jill Conner</name><name sortKey="Mathena, Julie" sort="Mathena, Julie" uniqKey="Mathena J" first="Julie" last="Mathena">Julie Mathena</name><name sortKey="Rhyee, Sean H" sort="Rhyee, Sean H" uniqKey="Rhyee S" first="Sean H" last="Rhyee">Sean H. Rhyee</name></noCountry><country name="Canada"><noRegion><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000652 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000652 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25314256
|texte= Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25314256" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |